Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Exon 20 Insertion Mutation”

53 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 53 results

Large-scale testing (Phase 3)Active Not RecruitingNCT05607550
What this trial is testing

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Who this might be right for
Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung CancerEGFR Exon 20 Mutations
ArriVent BioPharma, Inc. 398
Testing effectiveness (Phase 2)Active Not RecruitingNCT05751187
What this trial is testing

Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients

Who this might be right for
Non-squamous NSCLC
Shanghai Chest Hospital 54
Early research (Phase 1)Active Not RecruitingNCT05364073
What this trial is testing

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc. 160
Testing effectiveness (Phase 2)Active Not RecruitingNCT07274761
What this trial is testing

Neoadjuvant Sunvozertinib in Stage II-IIIB Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutation.

Who this might be right for
Potentially Resectable EGFR Exon 20 Insertion Non-Small Cell Lung CancerNon Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 24
Large-scale testing (Phase 3)Looking for participantsNCT07182682
What this trial is testing

Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery

Who this might be right for
Non-Small Cell Lung Cancer
Dizal (Jiangsu) Pharmaceutical Co., Ltd. 360
Large-scale testing (Phase 3)Active Not RecruitingNCT05668988
What this trial is testing

DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Who this might be right for
Non-small Cell Lung Cancer
Dizal Pharmaceuticals 324
Large-scale testing (Phase 3)Active Not RecruitingNCT05973773
What this trial is testing

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

Who this might be right for
Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
Taiho Oncology, Inc. 285
Early research (Phase 1)UnknownNCT04448379
What this trial is testing

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Shanghai JMT-Bio Inc. 48
Testing effectiveness (Phase 2)Looking for participantsNCT03191149
What this trial is testing

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Who this might be right for
Advanced Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage IIIB Lung Non-Small Cell Cancer AJCC v7+1 more
National Cancer Institute (NCI) 46
Large-scale testing (Phase 3)Active Not RecruitingNCT04129502
What this trial is testing

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Who this might be right for
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Takeda 354
Testing effectiveness (Phase 2)Looking for participantsNCT06192849
What this trial is testing

To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Who this might be right for
Non Small Cell Lung CancerEGFR Exon 20 Insertion Mutation
Juan LI, MD 20
Early research (Phase 1)Not Yet RecruitingNCT05940116
What this trial is testing

A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors

Who this might be right for
Non-Small Cell Lung CancerSolid Tumor
Hansoh BioMedical R&D Company 322
Not applicableApproved For MarketingNCT04599712
What this trial is testing

Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Metastatic Non-Small Cell Lung Cancer
Janssen Research & Development, LLC
Early research (Phase 1)Study completedNCT06001671
What this trial is testing

Antitumor Activity and Safety of BEBT-109, a Novel EGFR Inhibitor, in Previously Treated NSCLC

Who this might be right for
NSCLC
Hunan Province Tumor Hospital 23
Not applicableStudy completedNCT05419700
What this trial is testing

A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non-small Cell Lung Cancer Participants With EGFR Exon 20 Insertion

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Takeda 76
Testing effectiveness (Phase 2)Ended earlyNCT03805841
What this trial is testing

Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions

Who this might be right for
NSCLC, Stage IVNSCLC Stage IIIBNSCLC, Stage IIIC+5 more
Rain Oncology Inc 41
Testing effectiveness (Phase 2)Looking for participantsNCT06864624
What this trial is testing

Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC

Who this might be right for
NSCLC
Tang-Du Hospital 27
Not applicableLooking for participantsNCT06247826
What this trial is testing

Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion

Who this might be right for
Non-small Cell Lung CancerEGFR Exon 20 Insertion Mutation
Groupe Francais De Pneumo-Cancerologie 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT05712902
What this trial is testing

Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)

Who this might be right for
Non-Small Cell Lung Cancer
Dizal Pharmaceuticals 104
Testing effectiveness (Phase 2)Ended earlyNCT03318939
What this trial is testing

Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

Who this might be right for
NSCLC
Spectrum Pharmaceuticals, Inc 648
Load More Results